Floatz logo

299 assets in Lung Cancer

Therapeutic assets addressing Lung Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Abemaciclib
Lung Cancer
Tango Therapeutics, Inc.P2CCC (52)
Adebrelimab
Lung Cancer
Hansoh BioMedical R&D CompanyP2CCC (52)
Bl-M14D1
Lung Cancer
SystImmune Inc.P3CCC (52)
Capmatinib
Lung Cancer
SWOG Cancer Research NetworkP2CCC (52)
Dostarlimab
Lung Cancer
iTeos Belgium SAP2CCC (52)
Ensartinib
Lung Cancer
Sun Yat-sen UniversityP2CCC (52)
hd204
Lung Cancer
Prestige Biopharma LimitedP3CCC (52)
Lorlatinib
Lung Cancer
SCRI Development Innovations, LLCP2CCC (52)
Para-Toluenesulfonamide
Lung Cancer
Zhou ChengzhiP3CCC (52)
Pemigatinib
Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2CCC (52)
Penpulimab
Lung Cancer
Degan LuP3CCC (52)
pf-08634404
Lung Cancer
PfizerP3CCC (52)
Sacituzumab Tirumotecan
Lung Cancer
Merck Sharp & Dohme LLCP2CCC (52)
Zipalertinib
Lung Cancer
Taiho Oncology, Inc.P3CCC (52)
Ceritinib
Lung Cancer
National Cancer Institute (NCI)P2CCC (51)
Defactinib
Lung Cancer
Emory UniversityP2CCC (51)
Denosumab
Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, ChinaP2CCC (51)
Domvanalimab
Lung Cancer
Arcus Biosciences, Inc.P2CCC (51)
Etrumadenant
Lung Cancer
Gilead SciencesP2CCC (51)
Hydroxychloroquine
Lung Cancer
N.N. Petrov National Medical Research Center of OncologyP2CCC (51)
[18f]f-resca-rt4
Lung Cancer
RenJi HospitalP2/3CCC (50)
[18F]F-RESCA-T4
Lung Cancer
RenJi HospitalP2/3CCC (50)
[68ga]ga-nota-rt4
Lung Cancer
RenJi HospitalP2/3CCC (50)
[68ga]ga-nota-t4
Lung Cancer
RenJi HospitalP2/3CCC (50)
Berzosertib
Lung Cancer
National Cancer Institute (NCI)P1/2CCC (50)
Necitumumab
Lung Cancer
Jonsson Comprehensive Cancer CenterP1/2CCC (50)
Romiplostim
Lung Cancer
Peking University People's HospitalP2CCC (50)
Telaglenastat
Lung Cancer
National Cancer Institute (NCI)P1/2CCC (50)
Iodixanol
Lung Cancer
Brian Henick, MDP1/2CCC (49)
Aguix
Lung Cancer
Brigham and Women's HospitalP2CCC (48)
Autologous Immune Cells
Lung Cancer
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.P1/2CCC (48)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Lung Cancer
Rapa Therapeutics LLCP1/2CCC (48)
Avzo-1418
Lung Cancer
Avenzo Therapeutics, Inc.P1/2CCC (48)
Benzamide, 3-((3-Endo)-8-(2-((Cyclohexylmethyl)((2S)-2,3-Dihydroxy-1-Oxopropyl)Amino)Ethyl)-8-Azabicyclo(3.2.1)Oct-3-Yl)-
Lung Cancer
HealthPartners InstituteP2CCC (48)
Cbp-1019
Lung Cancer
Coherent Biopharma (Hefei) Co., Ltd.P1/2CCC (48)
Cis-Dpi
Lung Cancer
Inhatarget TherapeuticsP1/2CCC (48)
Datopotamab Deruxtecan
Lung Cancer
Latin American Cooperative Oncology GroupP2CCC (48)
Elironrasib
Lung Cancer
Revolution Medicines, Inc.P1/2CCC (48)
her3-dxd
Lung Cancer
Daiichi SankyoP2CCC (48)
Hrs-4508
Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.P2CCC (48)
Idarubicin
Lung Cancer
Second Affiliated Hospital of Guangzhou Medical UniversityP2CCC (48)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-48*01 (90.8%) -(Ighd) -Ighj4*01 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg1*01, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-16*01 (89.5%) -Igkj4*01 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform Alfa
Lung Cancer
Gilead SciencesP2CCC (48)
kb707
Lung Cancer
Krystal Biotech, Inc.P1/2CCC (48)
Leflunomide
Lung Cancer
N.N. Petrov National Medical Research Center of OncologyP2CCC (48)
mk-1084
Lung Cancer
Merck Sharp & Dohme LLCP1/2CCC (48)
Olomorasib
Lung Cancer
UNC Lineberger Comprehensive Cancer CenterP2CCC (48)
Opnurasib
Lung Cancer
Novartis PharmaceuticalsP1/2CCC (48)
Oral Restorative Microbiota Therapy
Lung Cancer
Masonic Cancer Center, University of MinnesotaP2CCC (48)
Patritumab Deruxtecan
Lung Cancer
Merck Sharp & Dohme LLCP1/2CCC (48)
qbs72s
Lung Cancer
Stanford UniversityP2CCC (48)
Showing 101 to 150 of 299 assets
PreviousPage 3 of 6Next